2023
Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma
Khang M, Lee J, Lee T, Suh H, Lee S, Cavaliere A, Rushing A, Geraldo L, Belitzky E, Rossano S, de Feyter H, Shin K, Huttner A, Roussel M, Thomas J, Carson R, Marquez-Nostra B, Bindra R, Saltzman W. Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma. Science Translational Medicine 2023, 15: eadi1617. PMID: 37910601, PMCID: PMC11078331, DOI: 10.1126/scitranslmed.adi1617.Peer-Reviewed Original ResearchConceptsCerebrospinal fluidDelivery of drugsEffective therapyTherapeutic indexPARP inhibitorsBlood-brain barrierSite of tumorRapid systemic clearanceXenograft mouse modelSolvent evaporation processAdministration of substancesLeptomeningeal spreadIntrathecal deliveryLeptomeningeal metastasesBrain penetrationSystemic clearanceTumor regressionPolymer nanoparticlesMetastatic medulloblastomaMouse modelPediatric medulloblastomaDrug accumulationCSF turnoverEncapsulated drugsPET imaging
2013
Increased Brain Lactate Concentrations Without Increased Lactate Oxidation During Hypoglycemia in Type 1 Diabetic Individuals
De Feyter HM, Mason GF, Shulman GI, Rothman DL, Petersen KF. Increased Brain Lactate Concentrations Without Increased Lactate Oxidation During Hypoglycemia in Type 1 Diabetic Individuals. Diabetes 2013, 62: 3075-3080. PMID: 23715622, PMCID: PMC3749358, DOI: 10.2337/db13-0313.Peer-Reviewed Original ResearchConceptsBrain lactate concentrationBlood-brain barrierHypoglycemia unawarenessLactate concentrationT1D subjectsControl subjectsType 1 diabetic subjectsType 1 diabetic individualsBlood-borne lactateNondiabetic control subjectsPlasma lactate concentrationMonocarboxylic acid transportDiabetic subjectsHypoglycemic clampT1D patientsDiabetic individualsBrain metabolismBrain fuelBrain glutamateBrain energeticsHypoglycemiaPatientsMetabolic adaptationAcid transportSubjects